Weekend Funding Roundup:
Mar 21, 2026
The week closed with biotech quietly commanding serious capital. Imperative Care raised $100M for stroke treatment robotics, while R1 Therapeutics launched from stealth with a $77.5M Series A. Bluesky disclosed a previously unannounced $100M Series B amid a CEO transition. Nearly $300M flowed into life sciences this week alone, a reminder that not all venture capital is chasing AI. Meanwhile, Blue Origin filed plans for 51,600 orbital data center satellites.
Rounds
Bluesky disclosed a previously unannounced $100M Series B that closed in spring 2025. The decentralized social network, built on the open AT Protocol, has grown from 13 million to over 43 million users. More than 1,000 third-party apps have been built on ATProto with 400,000 monthly developer tool downloads. The disclosure coincided with founder Jay Graber stepping down as CEO, replaced by interim CEO Toni Schneider (ex-Automattic CEO). The round values the platform's bet that social media's future is open and protocol-based, not walled-garden. Total raised: $123M.
Medtech company Imperative Care raised $100M via convertible note to advance its stroke treatment technology. The company already has three commercial products (Zoom Stroke System, Symphony and Prodigy Thrombectomy Systems) and is developing the Telos robotic platform for automated endovascular stroke treatment. Stroke is the leading cause of long-term disability globally, and the race to automate treatment is attracting serious capital. Total raised: $270M.
R1 Therapeutics launched from stealth with an oversubscribed $77.5M Series A to develop a first-in-class treatment for hyperphosphatemia in chronic kidney disease patients. AP306, a pan-phosphate transporter inhibitor licensed from China-based Alebund Pharmaceuticals, represents a new mechanism of action in a market where existing treatments have poor compliance. DaVita Venture Group and U.S. Renal Care on the cap table signals strong clinical validation from the dialysis operators who would actually use the drug.
Also Noted
Cancer immunotherapy startup raised $77M led by Taiho Ventures and Arkin Bio Capital with Pfizer Ventures, Eli Lilly, and others. Developing TCR-mimetic antibody therapies (T-Bolt) that target cancer cells in a novel way. Lead candidate CBX-250 is in Phase 1 for myeloid cancers with data expected by end of 2026.
Macrocyclic peptide therapeutics company raised $45M led by The Venture Collective with argenx and Merck's Global Health Innovation Fund. The platform combines parallel experimentation and ML to develop oral drugs against previously undruggable targets. Also signed a Novartis licensing deal worth up to $1.7B in milestones.
News & Signals
Blue Origin files for 51,600-satellite orbital data center constellation
Jeff Bezos's Blue Origin filed an FCC application for Project Sunrise: 51,600 satellites to create orbital data centers. This joins SpaceX (which has filed for 1 million satellites) and Starcloud (88,000) in the emerging space compute race. The thesis: as AI workloads demand more compute than Earth's power grid can supply, moving data centers to orbit (with unlimited solar power and natural cooling) becomes an engineering challenge worth solving. The filings are speculative, but the capital and intent behind them are real.
Biotech funding quietly surges as AI captures all the headlines
While AI mega-rounds dominate the narrative, biotech funding is having a strong week. Imperative Care ($100M), R1 Therapeutics ($77.5M), Crossbow Therapeutics ($77M), and Unnatural Products ($45M) represent nearly $300M in life sciences funding in a single week. The common thread: novel mechanisms of action in areas where existing treatments fail (stroke robotics, kidney disease, cancer immunotherapy, undruggable targets). Pharma strategics (Pfizer, Eli Lilly, Merck, argenx) are participating alongside traditional biotech VCs, suggesting genuine clinical conviction rather than hype cycles.
Bluesky's leadership transition tests decentralized social media's durability
Jay Graber stepping down as CEO of Bluesky while disclosing a $100M Series B raises a fundamental question: can a decentralized social network survive a leadership change? The answer may lie in the AT Protocol itself, which now has over 1,000 third-party apps. If the protocol layer is truly open and adopted, the company matters less than the ecosystem. Toni Schneider (ex-Automattic CEO, who shepherded WordPress from open-source project to commercial platform) is a revealing choice for interim CEO. The WordPress playbook, open protocol plus commercial services, may be Bluesky's path to sustainability.
VC Mood on X
The weekend brought a reflective tone to VC Twitter. The week's data point from TechCrunch, that AI startups now capture 41% of all venture dollars with 10% of startups taking 50% of funding, sparked soul-searching. Several seed investors argued the "K-shaped" market is worse than the numbers suggest: LPs are concentrating in a handful of mega-funds, which concentrate in a handful of mega-rounds, creating a self-reinforcing cycle that starves the rest of the ecosystem. The counter-argument: returns have been strong precisely because capital is flowing to the companies most likely to win.
Bluesky's CEO transition drew comparisons to other founder departures. The optimistic take: WordPress thrived after Matt Mullenweg built an ecosystem beyond himself, and the AT Protocol has enough third-party adoption to be self-sustaining. The pessimistic take: decentralized social networks have failed before (Diaspora, Mastodon's growth stalled), and losing the founding CEO during the scaling phase is a red flag. The crypto angle, Bain Capital Crypto leading the round, also raised questions about whether Bluesky's monetization will involve token economics.
Blue Origin's orbital data center filing generated the most speculative excitement. Space compute remains years away from commercial viability, but the convergence of unlimited solar power, natural cooling, and growing terrestrial power constraints makes the physics appealing. VCs noted that the real near-term opportunity is not in space data centers themselves but in the supply chain: radiation-hardened chips, satellite networking, thermal management, and ground station infrastructure. The Frore Systems ($143M for cooling) and Claros ($30M for power delivery) rounds earlier this week suddenly look prescient.
Rounds and signals sourced from SEC filings, press releases, and verified news reports. "Also Noted" covers smaller or less-documented deals. All amounts in USD unless noted. Reporting reflects information available at time of publication.